## Hydrophilic Polymer Driven Crystallization Self-assembly: Inflammation Multi-Drug Combination Nanosystem Against Alzheimer Disease

Haodong Hu<sup>a</sup>, Jinna Wang<sup>a</sup>, Jian Ren<sup>a</sup>, Xinpo Li<sup>a</sup>, Bo Zhang<sup>a</sup>, Zhengang Lv<sup>b\*</sup> and

Fengying Dai<sup>a\*</sup>

<sup>a</sup> State Key Laboratory of Separation Membranes and Membrane Processes/National Center for International Joint Research on Separation Membranes, School of Material Science and Engineering, Tiangong University, Tianjin 300387, China

<sup>b</sup> State Key Laboratory of Coal Conversion, Institute of Coal Chemistry, Chinese Academy of Sciences and Synfuels China Co., Ltd., Beijing, P. R. China

\*Corresponding author: Fengying Dai (email: daifengying@tjpu.edu.cn), Zhengang Lv (email: lzhg179@163.com)

## SUPPORTING INFORMATION



Fig. S1 GPC profiles of dextran and PCL-CTA polymers. (a) Elution time of Dex2K, Dex5K, Dex2K<sub>10</sub>, Dex5K<sub>4</sub> and Dex20K with water as an eluent, and the flow rate was 1.0 mL/min. (b) Elution time of PCL<sub>60</sub>-CTA and PCL<sub>130</sub>-CTA with THF as an eluent, and the flow rate was 1.0 mL/min.

	m <sub>PCL</sub> , <sup>a</sup>	p <sub>PPBA</sub> , <sup>b</sup>	n <sub>Dex</sub> , <sup>c</sup>	$M_n$ (g/mol), <sup>d</sup>	M <sub>n</sub> (g/mol), <sup>e</sup>	PDI (M <sub>w</sub> /M <sub>n</sub> ), <sup>f</sup>
sample	NMR	NMR	NMR	NMR	GPC	GPC
Dex2K	/	/	1	2000	2032	1.21
Dex5K	/	/	1	5000	5021	1.23
Dex20K	/	/	1	20000	19459	1.31
Dex5K <sub>4</sub>	/	/	4	20000	20415	1.26
Dex2K <sub>10</sub>	/	/	10	20000	19226	1.28
PCL <sub>60</sub> -CTA	60	/	/	7067	6971	1.35
PCL <sub>130</sub> -CTA	130	/	/	15047	15892	1.32
$PCL_{60}$ - <i>b</i> -PPBA <sub>10</sub>	60	10	/	8977	/	/
PCL <sub>130</sub> - <i>b</i> -PPBA <sub>10</sub>	130	10	/	16957	/	/
PCL <sub>130</sub> - <i>b</i> -PPBA <sub>120</sub>	130	120	/	37967	/	/
PCL <sub>130</sub> -g-Dex20K	130	/	1	35047	/	/
PCL <sub>130</sub> -g-Dex5K <sub>4</sub>	130	/	4	35047	/	/
$PCL_{130}$ -g-Dex $2K_{10}$	130	/	10	35047	/	/
PCL <sub>60</sub> -b-PPBA <sub>10</sub> -Dex20K	60	10	1	28977	/	/
PCL <sub>130</sub> -b-PPBA <sub>10</sub> -Dex20K	130	10	1	36957	/	/
PCL <sub>130</sub> - <i>b</i> -PPBA <sub>10</sub> -Dex5K <sub>4</sub>	130	10	4	36957	/	/
PCL <sub>130</sub> -b-PPBA <sub>10</sub> -Dex2K <sub>10</sub>	130	10	10	36957	/	/

 Table S1 Structural parameters of polymers.

٠

<sup>a</sup> m: DP of PCL as determined by <sup>1</sup>H-NMR measurement. <sup>b</sup> p: DP of PPBA as determined by <sup>1</sup>H-NMR measurement. <sup>c</sup> n: DP of dextran brush as determined by <sup>1</sup>H-NMR measurement. <sup>d</sup>  $M_n$ : Number-average molecular weight as calculated from DPs determined by <sup>1</sup>H-NMR measurement. <sup>e</sup>  $M_n$ : Number-average molecular weight as determined by GPC. <sup>f</sup> PDI: The ratio of weight-average molecular weight to number-average molecular weight as determined by GPC.



Fig. S2 Synthesis and characterization of polymers. (a) Synthesis Route of BSTSE and (b)  $^{1}$ H-NMR spectra of BSTSE in CDCl<sub>3</sub>.



**Fig. S3** Synthesis and characterization of polymers. (a) Synthesis Route of PBA and (b)  $^{1}$ H-NMR spectra of PBA in DMSO- $d_{6}$ .



Fig. S4 <sup>1</sup>H-NMR spectra of Dex2K, Dex5K and Dex20K in DMSO- $d_6$ .



Fig. S5 <sup>1</sup>H-NMR spectra of AC-Dex2K, AC-Dex5K and AC-Dex20K in DMSO-*d*<sub>6</sub>.



**Fig. S6** <sup>1</sup>H-NMR spectra of Dex2 $K_{10}$  and Dex5 $K_4$  in DMSO- $d_6$ .

٠



Fig. S7 <sup>1</sup>H-NMR spectra of PCL<sub>60</sub>-CTA and PCL<sub>130</sub>-CTA in DMSO- $d_6$ .



8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 Chemical Shift (ppm)

Fig. S8 <sup>1</sup>H-NMR spectra of  $PCL_{60}$ -*b*-PPBA<sub>10</sub>,  $PCL_{130}$ -*b*-PPBA<sub>10</sub> and  $PCL_{130}$ -*b*-PPBA<sub>120</sub> in DMSO-*d*<sub>6</sub>.



.

**Fig. S9** Synthesis and characterization of polymers. (a)Synthesis routes and (b) <sup>1</sup>H-NMR spectra of PCL<sub>130</sub>-*g*-Dex20K, PCL<sub>130</sub>-*g*-Dex5K<sub>4</sub> and PCL<sub>130</sub>-*g*-Dex2K<sub>10</sub> in DMSO- $d_6$ .



Fig. S10 FT-IR spectra of PBA, PCL<sub>130</sub>-CTA, PCL<sub>130</sub>-*b*-PPBA<sub>10</sub> and PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex20K.



**Fig. S11** Crystallization behavior and thermodynamic characterization of copolymers and nanoparticles. (a) WAXD patterns of PCL<sub>130</sub>-CTA, PPBA<sub>10</sub>, PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>, PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>, PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex20K, PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex5K<sub>4</sub> and PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex2K<sub>10</sub>. (b) SAXS patterns of PCL<sub>60</sub>-*b*-PPBA<sub>10</sub>-Dex20K, PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex20K, PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex5K<sub>4</sub> and PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex2K<sub>10</sub>. (c) DSC curves of Dex2K<sub>10</sub> and Dex5K<sub>4</sub>. (d-f) DSC curves of PCL<sub>130</sub>-CTA, PPBA<sub>10</sub>, PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>, PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex20K, PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex2K<sub>10</sub>. Dex5K<sub>4</sub> and PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex2K<sub>10</sub>.



Fig. S12 Crystallization behavior and thermodynamic characterization of copolymers. (a) WAXD spectrum and (b-d) DSC curves of  $PCL_{60}$ -CTA,  $PCL_{60}$ -*b*-PPBA<sub>10</sub> and  $PCL_{60}$ -*b*-PPBA<sub>10</sub> Dex20K.



.

**Fig. S13** Crystallization behavior and thermodynamic characterization of copolymers. (a) WAXD spectrum and (b-d) DSC curves of  $PCL_{130}$ -g-Dex20K,  $PCL_{130}$ -g-Dex5K<sub>4</sub>,  $PCL_{130}$ -g-Dex2K<sub>10</sub>,  $PCL_{130}$ -b-PPBA<sub>120</sub>.

None	NaCl	NaCl	SDS	SDS	SDS	DDBAC	DDBAC	DDBAC	Glucose	Glucose
	2.5% w/v	5.0% w/v	0.05% w/v	0.25% w/v	0.5% w/v	0.05% w/v	0.25% w/v	0.5% w/v	3.9 mM	6.4 mM
						N				

**Fig. S14** Stability test of PCL<sub>130</sub>-*b*-PPBA<sub>120</sub> vesicle dispersions. Photographs before and after NaCl (the final concentration: 2.5% w/v, 5% w/v), SDS (the final concentration: 0.05% w/v, 0.25% w/v), DDBAC (the final concentration: 0.05% w/v, 0.25% w/v, 0.5% w/v) and glucose (the final concentration: 3.9 mM, 6.4 mM) treatments (the final concentration of PCL<sub>130</sub>-*b*-PPBA<sub>120</sub> vesicle is 0.5% w/v).

 Table S2 Summary of PCL<sub>130</sub>-b-PPBA<sub>10</sub>-Dex20K micelle's stability test.

.

type of added surfactant or glucose	concentration (w/v %)	$D_{h}^{a}(nm)$	PDIª	T <sup>b</sup> (%)
none (i.e., pristine PCL <sub>130</sub> -b- PPBA <sub>10</sub> -Dex20K micelle)	0.0	132.4	0.053	12.2
	2.5	133.6	0.062	12.5
NaCI	5.0	132.5	0.065	12.3
SDS	0.05	133.7	0.081	12.7
	0.25	134.6	0.076	11.9
	0.5	137.2	0.091	12.6
DDBAC	0.05	136.5	0.065	12.4
	0.25	138.2	0.063	12.7
	0.5	137.3	0.057	12.5
1	0.07	136.5	0.056	12.3
glucose	0.12	137.4	0.058	12.6

type of added surfactant or glucose	concentration (w/v %)	$D_{h}^{a}(nm)$	PDIª	T <sup>b</sup> (%)
none (i.e., pristine PCL <sub>130</sub> -b- PPBA <sub>10</sub> -Dex5K <sub>4</sub> vesicle)	0.0	173.8	0.062	13.1
	2.5	174.7	0.064	13.4
NaCI	5.0	173.5	0.086	13.6
SDS	0.05	176.2	0.053	12.9
	0.25	177.5	0.066	13.5
	0.5	176.8	0.062	13.2
	0.05	179.2	0.095	13.7
DDBAC	0.25	175.3	0.062	13.5
	0.5	169.5	0.057	12.9
1	0.07	173.2	0.057	13.2
glucose	0.12	174.6	0.064	13.1

**Table S3** Summary of PCL130-*b*-PPBA10-Dex5K4 vesicle's stability test.

•

type of added surfactant or glucose	concentration (w/v %)	$D_{h}^{a}\left( nm ight)$	PDI <sup>a</sup>	T <sup>b</sup> (%)
none (i.e., pristine PCL <sub>130</sub> -b- PPBA <sub>10</sub> -Dex2K <sub>10</sub> vesicle)	0.0	156.8	0.071	12.6
	2.5	157.3	0.065	12.8
NaCI	5.0	158.3	0.061	13.2
SDS	0.05	154.6	0.057	12.5
	0.25	155.8	0.064	12.6
	0.5	157.3	0.092	12.8
DDBAC	0.05	156.3	0.110	12.5
	0.25	158.3	0.066	12.7
	0.5	157.6	0.085	13.2
1	0.07	157.3	0.065	12.3
glucose	0.12	157.8	0.071	12.2

Table S4 Summary of PCL<sub>130</sub>-*b*-PPBA<sub>10</sub>-Dex2K<sub>10</sub> vesicle's stability test.

•

type of added surfactant or glucose	concentration (w/v %)	$D_{h}^{a}\left( nm ight)$	PDIª	T <sup>b</sup> (%)
none (i.e., pristine PCL <sub>130</sub> -b- PPBA <sub>120</sub> vesicle)	0.0	121.3	0.053	12.6
	2.5	814.3	0.252	35.2
NaCI	5.0	1151.2	0.731	82.3
SDS	0.05	752.3	0.364	34.2
	0.25	892.1	0.536	46.2
	0.5	1021.6	0.643	56.3
DDBAC	0.05	101.3	0.151	10.2
	0.25	75.3	0.216	8.3
	0.5	42.1	0.263	6.4
1	0.07	834.2	0.342	42.1
glucose	0.12	1022.5	0.642	65.2

**Table S5** Summary of PCL130-*b*-PPBA120 vesicle's stability test.

٠



Fig. S15 The typical escape routes of each group mice in the morris water maze on the fifth day.



Fig. S16 The swimming speed of each group on the fifth day.



Fig. S17 The immunohistochemical analysis of  $A\beta_{1-42}$  deposition in the hippocampus and cortex of mice. Scale bars = 50 µm.



**Fig. S18** The delivery efficiency and biodistribution data of micelle. (a) Ex vivo fluorescence tissue images of SAMP8 mice after treated with (i)  ${}^{C6}PCL_{130}$ -*b*-PPBA<sub>10</sub>-Dex20K micelle or (ii) coumarin 6 (C6). (b) The biodistribution of  ${}^{C6}PCL_{130}$ -*b*-PPBA<sub>10</sub>-Dex20K micelle and coumarin 6 2 hours after nasal administration. Scale bars = 5 mm.



Fig. S19 H&E staining pictures of heart, liver, spleen and lung in each group of mice (100X). Scale bars =  $50 \ \mu m$ .